Company News

Qkine and Enantis sign a licensing deal to bring hyperstable FGF2-STAB® to the global stem cell community

Cambridge University spin-out, Qkine, and Enantis, a biotechnology spin-off company from Masaryk University, have concluded a licensing deal for Qkine to use Enantis’s patented FGF2-STAB® technology globally and develop new product-lines based on the unique biochemical properties of the protein. FGF2-STAB® is a hyperstable form of FGF-2 (bFGF), a core reagent for stem cell culture. This optimised form of the protein does not degrade in culture media leading to a range of applications in enhanced weekend-free stem cell culture media and advanced chemically defined systems, such as those needed in the cultured meat industry. Read more

Related stories

Read More

Tucked inside the Trinity Centre is one of the Park’s most unexpected high-performance environments: a Brazilian Jiu-Jitsu academy run by Leo ...

Read More

Cambridge Science Centre, based at the Park’s Trinity Centre, has unveiled a bold new five-year strategy designed to help secure ...

Read More

Billy Boyle, founder and CEO of Owlstone Medical, is turning endurance into action and inviting others to join him and ...

Want to see your news featured here? Contact the team and let’s spread the word.